Blinatumomab

Blinatumomab

Monoclonal antibody
Type	Bi-specific T-cell engager
Source	Template:Infobox drug/mab source
Target	CD19, CD3
Identifiers
CAS Number	853426-35-4
ATC code	none
Chemical data
Formula	C2367H3577N649O772S19
Molar mass	54.1 kDa[[]]

Blinatumomab (MT103) is a drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.

The drug was developed by a German-American company Micromet, Inc. in cooperation with MedImmune.

Structure and mechanism of action

File:BiTE antibody en.svg

Blinatumomab linking a T cell to a malign B cell.

Blinatumomab enables a patient's T cells to recognize malign B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell.

Therapeutic use

In a phase 1 clinical study with blinatumomab, patients with non-Hodgkin's lymphoma showed tumor regression, and in some cases complete remission. There are ongoing phase 1 and phase 2 clinical trials of blinatumomab in patients with acute lymphoblastic leukemia (ALL), lung or gastrointestinal cancers.

References

de:Blinatumomab es:Blinatumomab